🇺🇸 FDA
Pipeline program

HMB-001

HMB-001-CL101

Phase 2 small_molecule active

Quick answer

HMB-001 for Glanzmann Thrombasthenia is a Phase 2 program (small_molecule) at Hemab Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Hemab Therapeutics Holdings
Indication
Glanzmann Thrombasthenia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials